Crystallloids and colloids

MEA Kemp

Department of Anaesthesia, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, South Africa
Corresponding author, email: meakemp@mweb.co.za

Summary

Administration of intravenous fluid is like giving drugs, in that they have both beneficial and harmful effects. The composition of intravenous crystalloid and colloid fluids used for resuscitation is described in detail. The use of fluids for intravascular volume replacement is discussed as well as some of the controversies of this in haemorrhagic shock and septic shock.

Keywords: composition of crystalloids, colloids, use of fluids in haemorrhagic and septic shock

Introduction

The invention1 of plastic tubing and catheters in the 1950s made it possible to administer large volumes of fluid intravenously to patients. This use has led to the realisation that intravenous fluids have both beneficial and adverse effects.

Intravenous fluids are drugs

Malbrain et al.2 advocates for considering all intravenous fluids in the same manner as any other drug and for using the concept of ‘four Ds’ when prescribing fluids:

Drug – consider the indication for the fluid and what effect is being sought.

Duration of therapy – consider when to start and when to stop therapy.

Dosing – consider how much fluid to give.

De-escalation – consider when the fluid therapy is no longer effective or required.

Indications for intravenous fluids

There are four main indications for intravenous fluid therapy:

1. Resuscitation. A volume expander is an intra-venous fluid that functions to provide volume for the circulatory system.

2. Maintenance or replacement of total body water and electrolytes.

3. A carrier for medication.

4. A carrier for parenteral nutrition.

Types of intravenous fluids

**Crystalloids**

Crystalloid refers to an intravenous solution that contains water, electrolytes and/or non-electrolyte solutes capable of entering all body fluid compartments. Crystalloid solutions can be isotonic, hypertonic, or hypotonic with regard to plasma. Isotonic fluids act to expand the total body water volume without disturbing ion concentrations or causing large fluid shifts. Hypertonic solutions, such as 3% saline, and hypotonic solutions, such as 5% dextrose water, are osmotically active and cause fluid shifts. The use of these fluids will not be discussed here.

The strong ion difference (total anions in solution – total cations in solution) determine, in part, the pH of the fluid. Substances such as acetate, malate, gluconate and lactate are added to crystalloids in order to buffer the solution to a more physiological

<table>
<thead>
<tr>
<th>Constituent mmol/l</th>
<th>Plasma</th>
<th>0.9% saline ‘normal saline’</th>
<th>Ringer’s lactate</th>
<th>Plasmalyte B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na+</td>
<td>136–145</td>
<td>154</td>
<td>131</td>
<td>130</td>
</tr>
<tr>
<td>K+</td>
<td>3.5–5</td>
<td>5</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Mg++</td>
<td>0.8–1</td>
<td>1.8</td>
<td>1.5 (hexahydrate 0.3 g)</td>
<td></td>
</tr>
<tr>
<td>Ca++</td>
<td>2.2–2.6</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cl-</td>
<td>98–106</td>
<td>154</td>
<td>112</td>
<td>110</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td></td>
<td></td>
<td></td>
<td>27</td>
</tr>
<tr>
<td>Lactate</td>
<td></td>
<td></td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Strong ion difference</td>
<td>42</td>
<td>27</td>
<td>28</td>
<td>50</td>
</tr>
<tr>
<td>Theoretical osmolality</td>
<td>291</td>
<td>308</td>
<td>279</td>
<td>294</td>
</tr>
<tr>
<td>Actual osmolality</td>
<td>287</td>
<td>286</td>
<td>265</td>
<td>271</td>
</tr>
<tr>
<td>pH</td>
<td>7.45</td>
<td>5.5</td>
<td>6.75</td>
<td>7.4</td>
</tr>
</tbody>
</table>
pH. These are metabolised to bicarbonate in vivo. Bicarbonate (HCO₃⁻) is incompatible with solutions containing calcium.

The two key differences between normal saline and the other crystalloids are the presence of additional anions in Ringer’s and Plasmalyte, and the relative excess of chloride ions in normal saline. Hyperchloraemia from administration of normal saline can cause acidosis. This is usually self-limiting, although there are associated adverse outcomes, including excessive expansion of the extra-cellular fluid, platelet activation, decreased thrombin generation and renal dysfunction.

**Colloids**

In the context of intravenous fluids, a colloid refers to a high molecular weight substance present in a crystalloid solution that initially remains largely within the intravascular space, thereby generating an oncotic pressure. Colloids are either natural, for example, human albumin, or artificial, being either gelatin derivatives, hydroxyethyl starch (HES) or dextran (Table II).

The molecular weight (MW) of a colloid determines the viscosity of the solution. The total weight of the colloid divided by the number of molecules present in solution is called the number average molecular weight (MN) and determines the oncotic pressure. Albumin is monodisperse (albumin molecules are all the same, so MW = MN), but all artificial colloids are polydisperse, with a range of molecule sizes.

Albumin and gelatins have a physiological pH, and HES is acidic. The oncoticity (number of molecules in solution) influences the degree of volume expansion – the higher the oncotic pressure, the greater the initial volume expansion. Plasma half life depends on the molecular weight, the elimination route and the organs involved in elimination. This varies with disease states, anaesthesia and surgery. Oncotic pressure is less effective when capillary permeability is increased.

**Albumin**

Albumin contributes to about 80 % of the normal oncotic pressure exerted by plasma. It is a single polypeptide chain with 585 amino acids. Albumin is a natural colloid with few side effects. It is negatively charged, contributing to the formation of a normal ion gap. The high cost of albumin is its main disadvantage.

**Hydroxyethyl starches**

These are derivatives of amylopectin, a starch resembling glycogen, derived from maize. Hydroxyethyl groups are added to stabilise the molecule. The 6% solution is iso-oncotic with plasma and is polydisperse, with molecules ranging in size from 70 kDa to 450 kDa. The smaller molecules are rapidly excreted. The continuous excretion reduces the osmotic pressure, a process partially compensated for by degradation of larger particles.

The earlier HES fluids were associated with coagulation dysfunction and pruritis, but the tetrastarches used these days have no effect on bleeding times. Renal impairment in critically ill patients is associated with osmotic nephrosis like lesions in the proximal and distal tubules.

**Gelatins**

Gelatins are large polypeptides obtained by hydrolysis of collagen, with either succinylated (gelofusine) or urea cross-linked (haemacel) polypeptides and an average MW of 35 000 kDa. The carrier is a balanced salt solution. Gelofusine is compatible with blood but haemacel contains calcium.

Gelatins are rapidly excreted by the kidneys, and their duration of action is shorter than that of albumin. There is no evidence of renal dysfunction associated with gelatins. They are the cheapest colloid available, with a shelf life of three years, and there is no upper transfusion limit.

The main disadvantage of gelatins is the occurrence of anaphylactoid reactions, although the exact incidence of this is unclear. The effect on coagulation is also not clear, but they possibly activate coagulation. They do cause increases in plasma renin and aldosterone levels.

**Dextrans**

Dextrans are polydisperse, highly branched polysaccharide molecules. They are not used for volume expansion because of a high incidence of anaphylactic reactions and negative effects on coagulation. They are used to improve micro-circulation flow
in micro-surgical implantations, where the decrease in blood viscosity and inhibition of erythrocyte aggregation are useful.

**Use of intravenous fluid for intravascular volume replacement**

The loss of intravascular volume, and not loss of the oxygen carrying capacity of the blood, is the central mechanism of death in haemorrhagic shock.

**Fluid replacement in haemorrhagic shock**

Replacement of intravascular volume with albumin and dried plasma has been used since the First World War, when it was also observed that survivors of shock exhibited fluid and salt retention after the initial resuscitation phase. Shires and colleagues in the 1960s popularised the notion that shock was associated with the loss of large amounts of intravascular and extra-cellular fluids. Resuscitation with large volumes of crystalloid solutions was usual in the Vietnam War – with a corresponding increase in the incidence of ‘Da Nung’ lung, or acute respiratory distress syndrome (ARDS).

In the 1980s, Shoemaker reported an association between increased cardiac output, oxygen delivery and survival in critically injured patients, and this resulted in large volumes of crystalloid fluid being given to patients. Not only did this prove to have no survival benefit, but resulted in widespread oedema and hypertension, dilutional coagulopathy, ARDS, with increased mortality.

The ROSE² principle has been advocated for in the rational use of fluids in all types of shock. This requires consideration for the various stages involved in fluid therapy, namely:

- Resuscitation phase
- Optimisation phase
- Stabilisation phase
- Evacuation phase

As a result of the wars in Afghanistan and Iraq, a major paradigm shift in the management of haemorrhagic shock has occurred with the development of damage control resuscitation (DCR).

**Damage control resuscitation**

The resuscitation of the severely injured and bleeding patient depends just as much on normalising deranged physiology as it does on rapid surgical control of bleeding, and optimal fluid management is key to resuscitation.

Traditionally, severe haemorrhagic shock was treated with infusion of crystalloids, followed sequentially by transfusion of packed red blood cells (PRBC), plasma and platelets. The DCR protocol relies on the early recognition of patients who are going to require massive transfusions (MT) – variously defined but often as requiring ten or more units of PRBC in 24 hours and activation of a massive transfusion protocol (MTP). This has been shown to be associated with a reduced incidence of organ failure and reduced blood product wastage.

**DCR principles**

1. Limit the use of crystalloids during resuscitation by early use of transfusion with balanced ratios of PRBC, plasma and platelets.

The PROMTT (prospective, observational, multicentre major trauma transfusion) study in severe trauma patients revealed that early utilisation of transfusion with PRBC, plasma and platelets in ratios of 1:1 or 1:2, with 1 unit of platelets given for every 6–8 units of blood was associated with decreased mortality as compared to other fluid administration regimes. It also revealed that increased crystalloid use was associated with an increase in moderate and severe hypoxia. Although the underlying mechanism of the benefit of the blood, plasma and platelet transfusion regime remains unclear, one hypothesis suggests that the liberal use of crystalloids and artificial colloids increase hydrostatic pressure without repairing endothelial glycocalyx damage, resulting in increased capillary permeability. The infusion of plasma can be complicated by transfusion related acute lung injury (TRALI), characterised by inflammatory mediated pulmonary oedema occurring within hours of transfusing blood products.

2. Permissive hypotension until control of haemorrhage is achieved.

Animal models of haemorrhagic shock suggest that a mean arterial pressure of greater than 60 mmHg is associated with ‘popping’ of blood clots and rebleeding. A study in humans showed no difference in survival in patients with a systolic blood pressure of 70 mmHg versus those with a systolic blood pressure of 100 mmHg.

The exact levels of permissible hypotension are uncertain. A reasonable approach appears to be that in the presence of penetrating trauma, systolic blood pressures of 60–70 mmHg are acceptable. In the case of blunt trauma, systolic pressures of 80–90 mmHg are acceptable and in the presence of traumatic brain injury (TBI), systolic blood pressures of 100–110 mmHg should be maintained.

3. Goal-directed correction of coagulopathy with the use of thromboelastography (TEG) or rotational thromboelastography (ROTEM) and administration of specific clotting factors.

**Hypertonic saline resuscitation**

Several in vitro and in vivo studies show benefits of using hypertonic saline solutions as an initial resuscitation fluid but the Resuscitation Outcomes Consortium (ROC) performed a multicentre, randomised trial which revealed a worse incidence of coagulopathies with hypertonic saline as compared with normal saline, although there was no difference in mortality between the two.

**Fluid replacement in septic shock**

The rationale for assuming that the shock associated with severe sepsis is caused by decreased tissue perfusion is based upon the occurrence of systemic hypotension, increased blood lactate...
levels and oliguria. This has resulted in the concept of intravascular volume expansion being extended to the treatment of septic shock, although the evidence that increased blood lactate levels in septic shock are indicative of tissue hypoperfusion is lacking.

Volume expansion therapy is commonly used in septic shock and there is evidence that this does improve morbidity and mortality. The evidence for what fluid and how much should be used remains weak and conflicted. Fluid is less likely to remain intravascularly in sepsis, and there is always a risk of fluid overload when using fluids to treat any type of shock.

Rivers suggested that early, goal-directed fluid therapy (EGDFT) main intravascularly in sepsis, and there is always a risk of fluid be used remains weak and conflicted. Fluid is less likely to re-

not substantiated that the use of EGDFT is carried out correctly Although three recent large randomised controlled trials have not substantiated that the use of EGDFT is carried out correctly

However, three recent large randomised controlled trials have not substantiated that the use of EGDFT is carried out correctly (Table III). Safety limits are not followed, and patients often do not receive less fluid than with conventional therapy.

Current recommendations of the World Health Organization (WHO) are that 30 ml/kg of fluid should be given to patients with septic shock in the first three hours. However, in a trial of Ugandan children with severe sepsis due to malaria, a rapid initial bolus of 20–40 ml/kg of normal saline was associated with increased 48-hour mortality. In another study of severe sepsis fluid treatment in Uganda, there was no difference in outcomes if patients received fluids according to the WHO guidelines, or not.

The debate: colloids versus crystalloids

The controversy surrounding whether crystalloids or colloids should be used for volume expansion remains. Colloids theoretically have the advantage of remaining intravascularly for longer than crystalloids and thereby allow for limiting the amount of fluid therapy received as compared to a crystalloid resuscitation. While a transfusion lasts, crystalloids and colloids exert a similar volume expansion effect. Simulations suggest that the intravascular half-life (T ½) of colloids is 20–40 minutes, although this may be extended during anaesthesia. Colloids have an intravascular T ½ of 2–3 hours, but the distribution, elimination and excretion of colloid molecules are affected by vascular permeability, hypotension, general anaesthesia and surgery. The endothelial glyocalyx lines the luminal aspect of the vascular endothelium and influences the permeability of fluids across the endothelial barrier. This is damaged in both septic and haemorrhagic shock and this is associated with poorer outcomes. Infusing a colloid solution into a patient with a degraded endothelial glyocalyx may cause interstitial protein/colloid accumulation, resulting in tissue oedema like that caused by infusion of crystalloids. Infusing colloids similarly cannot re-

verse pre-existing tissue oedema. The use of fresh frozen plasma as a resuscitation fluid may have superiority because of its ability to preserve the glyocalyx rather than its ability to restore coagulation factors. There is no evidence that albumin or crystalloid infusion preserves the glyocalyx.

Table III

<table>
<thead>
<tr>
<th>Trial</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>VASST²²</td>
<td>There was no difference in outcomes if vasopressin or norepinephrine was used in septic shock. There is an inverse relationship between mortality and fluid administration.</td>
</tr>
<tr>
<td>FENICE¹³</td>
<td>Methods used to predict fluid responsiveness are highly variable; whether patients were deemed fluid responsive or not did not guide fluid management and safety limits for fluids were often ignored.</td>
</tr>
<tr>
<td>FACTT²⁴</td>
<td>Conservative fluid therapy significantly improves lung function in ARDS.</td>
</tr>
</tbody>
</table>

Table IV

<table>
<thead>
<tr>
<th>Trial</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>SALT²⁰</td>
<td>Among non-critically ill adults treated with intravenous fluids in the emergency department, there was no difference in hospital-free days between patients treated with balanced crystalloids or normal saline.</td>
</tr>
<tr>
<td>SPLIT²¹</td>
<td>Among patients receiving crystalloid therapy in intensive care, there was no difference in the incidence of acute kidney injury if a balanced salt solution or normal saline was used.</td>
</tr>
<tr>
<td>SMART²²</td>
<td>Among critically ill adults, the use of balanced crystalloids for intravenous fluid administration results in a lower composite death rate from any cause, as well as a lower rate of new renal replacement therapy or persistent renal dysfunction, than the use of normal saline.</td>
</tr>
<tr>
<td>CRISTAL²³</td>
<td>In critically ill patients with symptoms of hypovolaemic shock, use of colloids or crystalloids did not make any difference in 28-day mortality, although 90-day mortality was lower in the colloid group. Renal replacement therapy was similar in both groups.</td>
</tr>
<tr>
<td>CHEST²⁴</td>
<td>No significant difference in 90-day mortality in patients resuscitated with 6% HES or saline, but more patients who were resuscitated with HES required renal replacement therapy. Reanalysis of these results in 2017 showed some differences in secondary and tertiary outcomes but confirmed support for the original conclusions of the study.</td>
</tr>
</tbody>
</table>
A Rational, Pragmatic Algorithm for Perioperative Fluid Administration in Adults

A possible algorithm to manage perioperative fluid administration

- **ABP** < 20% baseline
  - or
  - **MAP** < 60 mmHg
  - **yes**

- Relative or absolute volume deficiency
  - or
  - SVV > 15%
  - PPV > 13%
  - no

- No fluid therapy
  - Consider vasopressor

- No renal insufficiency or sepsis?
  - yes
  - 6% HES 130/0.4
  - 1:1 to losses or optimisation

- Crystalloid bolus 4:1 to measured loss
  - no

- **Objectives achieved?**
  - yes
  - Maintenance fluid only

- **Low CO?**
  - yes
  - Consider inotropes

- **Cardiac evaluation:**
  - Known chronic heart failure?
  - Clinical signs for acute heart failure?
  - If unclear:
    - Echo
    - Thermodilution

- **Vasopressor**
  - Phenylephrine
  - Ephedrine
  - Noradrenaline

---


---

This treatment algorithm, adapted from Strunden et al. 2016 and edited by Prof. MFM James and Prof. AC Lundgren to align it to local clinical practice, is presented by Fresenius Kabi as a service for physicians. Fresenius Kabi does not stipulate exclusive use of its products.

**Voluven®** Reg. No. 34/8.4/0417. Each 100 ml contains: HES 130/0.4 g. Sodium chloride 0.9 g.

**Volulyte®** Reg. No. 41/8.4/0211. Each 100 ml contains: HES 130/0.4 g. Sodium acetate trihydrate 0.463 g. Sodium chloride 0.602 g. Potassium chloride 0.03 g. Magnesium chloride hexahydrate 0.03 g.

For full prescribing information refer to professional information approved by the South African Health Products Regulatory Authority.
HES solutions in vitro do show some protective effects that do not translate into clinical effects.

Colloids are more expensive and at present, there is no evidence of survival benefit in using colloids as opposed to crystalloids as a resuscitation fluid.

In the management of septic shock, it appears that use of HES results in greater renal dysfunction than the use of crystalloids although there was no difference in mortality.

Some trials have attempted to address the problem of which crystalloid to use and whether colloids or crystalloids should be used in the treatment of shock (Table IV).

The Cochrane Systematic Review of 2018 reviewed 69 randomised controlled trials (RCT) and ‘quasi’ RCT comparing the use of colloids and crystalloids in shock and summarised the evidence in the debate as follows:

There is moderately certain evidence that there is little or no difference between using starches, albumin, fresh frozen plasma or crystalloids in mortality at 90 days (RR 0.97; 95% CI).

There is moderately certain evidence that starches probably increase the need for blood transfusion (RR 1.19, 95% CI), and uncertain evidence that the use of albumin, fresh frozen plasma or crystalloids increase the need for blood transfusion (RR 0.98).

There is very low certainty evidence that starches cause allergic reactions.

Conclusion

Intravenous fluid therapy must be considered as a drug with benefits and adverse effects as well as many unanswered questions regarding its use.

Conflict of interest

The author declares no conflict of interest.

Funding source

None.

ORCID

MEA Kemp https://orcid.org/0000-0003-3061-5033

References